



Atrys achieves revenues of EUR 51.4 million and improves adjusted EBITDA by 17.2% in the first quarter of 2024

- *The company increased revenues by 6.9% in the first three months of the year compared to the same period in 2023, driven by growth in the Diagnostics and Oncology divisions.*
- *Adjusted EBITDA in the first three months improved by +17.2% to €9.1m, reflecting efficiency gains and OPEX cost containment.*
- *Atrys' first quarter of 2024 figures reflect the company's solid growth in all business segments and reiterate guidance for the full year*
- *The company has successfully completed the issue of contingent convertible bonds in the amount of 11.7 million euros, following the bond issue for an amount of 13.3 million euros notified to the CNMV last December.*

10 MAY 2024- Atrys Health (ATRY), a global healthtech company providing precision medical prevention, diagnosis and treatment services and a pioneer in telemedicine and oncology treatment, has announced its results for the first quarter of 2024, which reflect the company's strong performance in all business areas and reiterate its guidance for the full year (EUR 220-224 million).

During the first three months of 2024, Atrys reported revenues of 51.4 million euros, 6.9% higher than the 48.1 million euros recorded in the same period of 2023. All business segments grew in the first quarter of the year, with a particular increase in the Diagnostics area, followed by Oncology and Prevention.

Gross Margin grew by 6.4% to 34.9 million euros in the first quarter.

Adjusted EBITDA also improved notably, with a 17.2% growth compared to the same period of 2023, reaching EUR 9.1 million. At the same time, the improvement in efficiency together with the containment of OPEX in the first three months of the year resulted in an increase of 160 b.p. in the Group's adjusted EBITDA margin.

In the first three months of 2024, cumulative CAPEX investment amounted to EUR 2.9 million compared to EUR 4.5 million in the first quarter of 2023, mainly due to the reduction in maintenance and growth CAPEX.

Operating Cash Flow increased by 125% and Operating Cash Flow adjusted for non-recurring expenses increased by 92% compared to the first three months of 2023, due to the growth in EBITDA and the reduction in CAPEX investment.

The company has also successfully completed the issue of Contingent Convertible Bonds in the amount of 11.7 million euros this week, with the same terms and conditions as the issue of 13.3 million euros executed on 28 December 2023 by the company.

Isabel Lozano, CEO of Atrys, said: 'We successfully closed the first quarter of 2024, in line with our objectives for the year and maintaining our guidance for the year. In the coming months, our focus will be on strengthening the organic growth of our core business, relying on the most

innovative technologies that will enable us to improve healthcare, guarantee accessibility to quality medical services and consolidate our leadership in our main business areas: prevention, diagnostics and oncology’.

Strong performance in all its business areas

In the first three months of 2024, Atrys has consolidated its growth in its core business in both Spain and Latin America. Specifically, during the first quarter, the company's turnover in the Spanish market grew by 5.2% to 38.8 million euros.

In the Latin American market, turnover grew by 13.9% to 9.36 million euros, driven by the good performance of the telediagnosis activity in Chile, Brazil and Colombia, as well as the medical oncology activity in Mexico.

By business area, in the Prevention segment, the company recorded a 2.4% increase in turnover compared to 2023, with the adjusted EBITDA margin remaining stable.

Atrys' Oncology division maintained its leadership position in Spain and strengthened its growth in Latin America, with an 8.6% increase in revenues, boosted by the growth in revenues in Medical Oncology. The Oncology division's adjusted EBITDA margin increased +230 b.p. to 18.1% in the first three months of 2024 vs. 15.8% a year earlier, driven by lower operating expenses.

Lastly, the Diagnostics segment led growth, with revenues 11.8% higher than in the first three months of 2023, with strong growth in the Laboratory area (Pathology and Genetics), which increased revenues by 33.6%. The Diagnostics division improved its adjusted EBITDA margin by +210 b.p. to 19.1% in the first three months of 2024 vs. 17% in the same period last year, reflecting cost control and operating leverage.

Today, Friday 10 May, at 10:00h, Atrys' Q1 2024 results presentation webcast will take place. Register via this link <https://streamstudio.world-television.com/1445-2730-39726/es>

About Atrys

Atrys is a global healthtech company providing medical services that maximise efficiency in prevention, diagnosis and precision medical treatment through innovative technologies. It is a pioneer in telemedicine and oncology treatment. It has a team of more than 2,400 professionals, is present in seven countries in Europe and Latin America, and is the only listed company in the healthcare technology sector in Spain. The company structures its activity around two main business areas. On the one hand, precision medicine, which includes diagnostics (telemedicine, nuclear medicine, pathology and molecular anatomy) and oncology treatment (medical oncology and advanced radiotherapy); and on the other, preventive medicine, dedicated to prevention and health promotion, which serves more than one million people through its network of more than 200 branches.

Media Contact - Atrys

Diana Barriga Atrys dbarriga@atryshealth.com +34 649 042 525	Marta Estarellas Roman m.estarellas@romanrm.com +34 616 469 524
---	--